X
All Data
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
Lead Product(s): LUT-014
Therapeutic Area: Dermatology Product Name: LUT014
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2021
Details:
The trial will evaluate the efficacy and safety of two strengths of LUT014 Gel, 0.03% or 0.10%, applied once daily for 4 weeks, compared to placebo, in patients with mCRC who develop Grade 2 EGFR inhibitor-induced acneiform lesions, with a 4-week follow up period.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
